Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | FNTA | P49354 | 2/20 | 0.47 |
| ▸ | FNTB | P49356 | 2/20 | 0.47 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16485592 | 1.00 | ALDH1A1 (0.71) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL11806001 | 1.00 | ALDH1A1 (0.71) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL16673068 | 1.00 | ALDH1A1 (0.71) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL381049 | 1.00 | ALDH1A1 (0.71) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL8620391 | 1.00 | ALDH1A1 (0.71) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL11805997 | 1.00 | ALDH1A1 (0.71) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL5245886 | 0.89 | ALDH1A1 (0.57) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL3055807 | 0.89 | ALDH1A1 (0.57) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL3055805 | 0.89 | ALDH1A1 (0.57) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL11410939 | 0.85 | ALDH1A1 (0.96) | ALDH1A1ALOX15FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11407704-B2 | Process of vitamin K2 derivatives preparation | SIEC BADAWCZA LUKASIEWICZ-INSTYTUT CHEMII PRZEMYSLOWEJ IMIENIA PROFESORA IGNACEGO MOSCICKIEGO (PL) | 2022-08-09 | — | — | US | disclosed |
| US-20210317060-A1 | PROCESS OF VITAMIN K2 DERIVATIVES PREPARATION | SIEC BADAWCZA LUKASIEWICZ-INSTYTUT CHEMII PRZEMYSLOWEJ IMIENIA PROFESORA IGNACEGO MOSCICKIEGO (PL) | 2021-10-14 | — | — | US | disclosed |
| EP-2408447-A1 | PRENYLATED BISPHOSPHONATES AS ANTI-TUBERCULOSIS AGENTS | University of Iowa Research Foundation (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20100240612-A1 | Prenylated Bisphosphonates as Anti-tuberculosis Agents | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010108190-A1 | PRENYLATED BISPHOSPHONATES AS ANTI-TUBERCULOSIS AGENTS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2010-09-23 | — | — | WO | disclosed |
| US-3939202-A | MULTISTAGE | TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JA) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240612-A1 | Prenylated Bisphosphonates as Anti-tuberculosis Agents | GGPS1, FDPS, DCTPP1 | ALDH1A1 2663/4885ALOX15 1748/4885FNTA 8/4885 |
| US-11407704-B2 | Process of vitamin K2 derivatives preparation | PROC, VKORC1, VKORC1L1 | ALDH1A1 1623/4885ALOX15 2307/4885FNTA 656/4885 |
| US-20210317060-A1 | PROCESS OF VITAMIN K2 DERIVATIVES PREPARATION | PROC, VKORC1, VKORC1L1 | ALDH1A1 1623/4885ALOX15 2307/4885FNTA 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.